CytomX Therapeutics Price to Free Cash Flow Ratio 2014-2022 | CTMX
Historical price to free cash flow ratio values for CytomX Therapeutics (CTMX) since 2014.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| CytomX Therapeutics Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2023-03-23 |
1.69 |
|
0.00 |
| 2022-09-30 |
1.45 |
$-2.20 |
0.00 |
| 2022-06-30 |
1.83 |
$-2.14 |
0.00 |
| 2022-03-31 |
2.67 |
$-2.02 |
0.00 |
| 2021-12-31 |
4.33 |
$-1.88 |
0.00 |
| 2021-09-30 |
5.09 |
$-1.75 |
0.00 |
| 2021-06-30 |
6.33 |
$-1.85 |
0.00 |
| 2021-03-31 |
7.73 |
$2.73 |
2.83 |
| 2020-12-31 |
6.55 |
$2.57 |
2.55 |
| 2020-09-30 |
6.65 |
$2.43 |
2.73 |
| 2020-06-30 |
8.33 |
$1.91 |
4.36 |
| 2019-12-31 |
8.31 |
$-3.18 |
0.00 |
| 2019-09-30 |
7.38 |
$-3.28 |
0.00 |
| 2019-06-30 |
11.22 |
$-2.79 |
0.00 |
| 2019-03-31 |
10.75 |
$-2.41 |
0.00 |
| 2018-12-31 |
15.10 |
$-1.90 |
0.00 |
| 2018-09-30 |
18.50 |
$-0.56 |
0.00 |
| 2018-06-30 |
22.86 |
$-0.71 |
0.00 |
| 2018-03-31 |
28.45 |
$4.69 |
6.06 |
| 2017-12-31 |
21.11 |
$4.54 |
4.65 |
| 2017-09-30 |
18.17 |
$2.90 |
6.26 |
| 2017-06-30 |
15.50 |
$3.11 |
4.98 |
| 2017-03-31 |
17.27 |
$-2.01 |
0.00 |
| 2020-03-31 |
7.67 |
$-1.03 |
0.00 |
| 2016-12-31 |
10.99 |
$-0.11 |
0.00 |
| 2016-09-30 |
15.68 |
$-3.53 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.115B |
$0.070B |
|
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|
